Abstract
After being in the therapeutic wilderness for several decades, acute myeloid leukemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin for treatment of relapsed or refractory CD33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of gemtuzumab ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.
MeSH terms
-
Aged
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / pharmacokinetics
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Arsenicals / therapeutic use
-
Calicheamicins / metabolism
-
Chlorides / therapeutic use
-
Clinical Trials as Topic
-
Cytarabine / administration & dosage
-
Daunorubicin / administration & dosage
-
Daunorubicin / adverse effects
-
Drug Approval
-
Drug Evaluation, Preclinical
-
Drug Resistance, Neoplasm
-
Gemtuzumab / adverse effects
-
Gemtuzumab / pharmacokinetics
-
Gemtuzumab / therapeutic use*
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / immunology
-
Leukemia, Promyelocytic, Acute / drug therapy
-
Leukemia, Promyelocytic, Acute / genetics
-
Mice
-
Middle Aged
-
Multicenter Studies as Topic
-
Recurrence
-
Sialic Acid Binding Ig-like Lectin 3 / antagonists & inhibitors*
-
Sialic Acid Binding Ig-like Lectin 3 / genetics
-
Sialic Acid Binding Ig-like Lectin 3 / metabolism
-
Tretinoin / therapeutic use
Substances
-
Antineoplastic Agents
-
Antineoplastic Agents, Immunological
-
Arsenicals
-
CD33 protein, human
-
Calicheamicins
-
Chlorides
-
Sialic Acid Binding Ig-like Lectin 3
-
Cytarabine
-
Tretinoin
-
arsenic trichloride
-
Gemtuzumab
-
Daunorubicin